Candel Therapeutics Announces $80 Million Proposed Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused…
Pharmaceuticals, Biotechnology and Life Sciences
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused…
No impact at this time on the listing of the Company’s Ordinary Shares on NasdaqCompany intends to submit to Nasdaq…
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is…
Business combination closed November 13, 2024Raised $10 million of gross proceeds in connection with the business combinationAgreements are in place…
Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans…
PDUFA goal date is July 27, 2025COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today…
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage…
Focus on in vivo CRISPR-edited medicines based on Editas researchers’ recent scientific progress in multiple tissues: Achieved pre-clinical in vivo…
Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the…
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory…